US3795736A - 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent - Google Patents

5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent Download PDF

Info

Publication number
US3795736A
US3795736A US00283435A US3795736DA US3795736A US 3795736 A US3795736 A US 3795736A US 00283435 A US00283435 A US 00283435A US 3795736D A US3795736D A US 3795736DA US 3795736 A US3795736 A US 3795736A
Authority
US
United States
Prior art keywords
benzopyrano
hydroxy
dimethyl
methyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00283435A
Inventor
R Razdan
L Harris
H Pars
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHARPS ASS US
Sharps Associates
Original Assignee
Sharps Associates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sharps Associates filed Critical Sharps Associates
Application granted granted Critical
Publication of US3795736A publication Critical patent/US3795736A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Definitions

  • ABSTRACT OF THE DISCLOSURE A method of relieving pain in mammalian patients comprising administering a therapeutically efiective amount of 5,5-dimethyl hydroxy-8-(3-methyl-2-octyD-2-(2- propynyl) 1,2,3,4 tetrah'ydro 5H [l]benzopyrano- [3,4-d1pyridine to a patient.
  • This invention relates to a method of relieving pain using 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2 propynyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano- [3,4-d] pyridine as the analgesic agent.
  • analgesic agent which appears to be free from addiction liability.
  • the compound useful in the practice of this invention is represented by the formula
  • the compound can be prepared according to the method taught in US. Pat. No. 3,576,798.
  • 5,5-dimethyl-10-hydroxy-8-(3-methyl 2 octyl) 2 (2-propynyl)-1,2,3,4- tetrahydro-5H-[ 1]benzopyrano [3,4-d] pyridine is administered to mammalian patients suffering from pain in dosages of from 0.01 to 0.2 mg./kg. I.V. and from 2.5 to 40 mg./kg. p.o., preferably in divided doses, i.e., three to four times daily.
  • the analgesic activity of the compound was evaluated in the hot plate analgesic test, the acetic acid writhing test and the rat tail flick study.
  • the compound useful in the practice of this invention can be formulated into various pharmaceutically acceptable dosage forms such as tablets, capsules, pills and the like for immediate or sustained release, by combining the compound with a suitable pharmaceutically acceptable carrier or diluent according to methods well known in the art.
  • dosage forms may additionally include lubricants, excipients, binders, fillers, flavoring and sweetening agents and other therapeutically inert ingredients necessary for the formulation of the desired preparation.
  • a method of relieving pain in a mammalian patient suffering therefrom comprising administering to said patient a therapeutically effective amount of 5,5-dimethyl-lO-hydroxy-S-(3-methyl-2-octyl) 2 (2-propynyl)-1,2,3,4-tetrahydro-5H-[ 1 benzopyrano[ 3,4-d] pyridine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A METHOD OF RELIEVING PAIN IN MAMMALIAN PARTIENTS COMPRISING ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF 5,5-DIMETHYL - 10 - HYDROXY-8-(3-METHYL-2-OCTYL)-2-(2PROPYNYL) - 1,2,3,4 - TETRAHYDRO - 5H - (1)BENZOPYRANO(3,4-D)PYRIDINE TO A PATIENT.

Description

United States Patent 3,795,736 5,5-DIMETHYL 10 HYDROXY-8-(3-METHYL-2- 0CTYL)-2-(2-PROPYNYL) 1,2,3,4-TETRAHYDRO- H-[1] BENZOPYRANO[3,4-d]PYRIDINE AS AN ANALGESIC AGENT Louis Selig Harris, Chapel Hill, N.C., and Harry George Pars, Lexington, and Raj Kumar Razdan, Belmont, Mass., assignors to Sharps Associates, Cambridge, Mass. No Drawing. Filed Aug. 24, 1972, Ser. No. 283,435 Int. Cl. A61k 27/00 US. Cl. 424-263 2 Claims ABSTRACT OF THE DISCLOSURE A method of relieving pain in mammalian patients comprising administering a therapeutically efiective amount of 5,5-dimethyl hydroxy-8-(3-methyl-2-octyD-2-(2- propynyl) 1,2,3,4 tetrah'ydro 5H [l]benzopyrano- [3,4-d1pyridine to a patient.
DETAILED DESCRIPTION OF THE INVENTION This invention relates to a method of relieving pain using 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2 propynyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano- [3,4-d] pyridine as the analgesic agent.
While there are a number of currently available analgesic agents on the market, the search for improved analgesic agents has been continued, since a number of the more potent agents are classified as narcotics. That is, if it is necessary for patients to take analgesic agents such as codeine, morphine and the like over a prolonged period of time, the addiction liability is high. The present invention provides an analgesic agent which appears to be free from addiction liability.
5,5 dimethyl 10 hydroxy-8-(3-methyl-2-octyl)-2-(2- propynyl) 1,2,3,4 tetrahydro 5H [l]benzopyrano- [3,4-d]pyridine has previously been reported to be useful as a central nervous system depressant (see US. Pat. No. 3,576,798). It has now been found that the compound possesses analgesic activity.
The compound useful in the practice of this invention is represented by the formula The compound can be prepared according to the method taught in US. Pat. No. 3,576,798.
In the practice of this invention, 5,5-dimethyl-10-hydroxy-8-(3-methyl 2 octyl) 2 (2-propynyl)-1,2,3,4- tetrahydro-5H-[ 1]benzopyrano [3,4-d] pyridine is administered to mammalian patients suffering from pain in dosages of from 0.01 to 0.2 mg./kg. I.V. and from 2.5 to 40 mg./kg. p.o., preferably in divided doses, i.e., three to four times daily.
The analgesic activity of the compound was evaluated in the hot plate analgesic test, the acetic acid writhing test and the rat tail flick study.
In the hot plate analgesic test carried out according to the method of Woolfe, G. and MacDonald, A. D., J. Pharmacol. Exper. Therap., 80, 300 (1944), 5,5-dimethyl- 10-hydroxy-8-(3-methyl-2-octyl) 2 (2 propynyl)-l,2, 3,4-tetrahydro-5H-[1]benzopyrano[3,4d]pyridine has an I.V. ED of 0.16 mg./kg. (95 C.L.=0.11 to 0.20) and an oral ED of 7.7 mg./kg. (95% C.L.=4.1 to 12.7).
3,795,736 Patented Mar. 5, 1974 [Morphine exhibits an intravenous ED value in mice of 0.009 mg./kg. C.L.'=0.006 to 0.014) and an oral ED value of 12.6 mg./kg. (95% C.L.=9'.7 to 16.4)].
Analgesic activity was also evaluated via the acetic acid writhing method, modified from that described by Whittle Brit. J. Pharmacol., 22, 296 (1964). The number of writhes were counted for a 20 minute period beginning 5 minutes after the injection of the acid. Analgetic potency was calculated from the diiference between the test groups and their controls. The compound exhibits an intravenous ED value of 0.0-3 mg./kg. (95% C.L.'=0.02 to 0.04) and an oral ED' value of 4.3 mg./kg. (95% C.L. =3.2 to 5.9).
The analgesic activity of the compound useful in the practice of this invention in the acetic acid writhing test is summarized in the following tables:
TABLE I Acetic acid writhing test in mice (I.V.)
Dose mg./kg. p.o.: Percent inhibition The oral ED of codeine phosphate is 15.6 mg./kg. (95% C.L.=9' to 23).
Analgesic activity was also exhibited in the rat tail fiick study (DAmour and Smith, J. Pharmacol. Exper. Therap., 72: 74, 1941). The compound exhibits an intravenous ED value of 0.13 (95% C.L.=0.07 to 0.18) and an oral ED value of 13.8 mg./kg. (95% C.L.==4.5 to 23.9).
The compound useful in the practice of this invention can be formulated into various pharmaceutically acceptable dosage forms such as tablets, capsules, pills and the like for immediate or sustained release, by combining the compound with a suitable pharmaceutically acceptable carrier or diluent according to methods well known in the art. Such dosage forms may additionally include lubricants, excipients, binders, fillers, flavoring and sweetening agents and other therapeutically inert ingredients necessary for the formulation of the desired preparation.
We claim:
1. A method of relieving pain in a mammalian patient suffering therefrom comprising administering to said patient a therapeutically effective amount of 5,5-dimethyl-lO-hydroxy-S-(3-methyl-2-octyl) 2 (2-propynyl)-1,2,3,4-tetrahydro-5H-[ 1 benzopyrano[ 3,4-d] pyridine.
2. The method of claim 1 wherein said compound is administered in dosages of from 0.01 to 40 mg./kg. of body weight daily.
References Cited UNITED STATES PATENTS 3,576,798 4/1971 Pars et a1. 260240 STANLEY J. FRIEDMAN, Primary Examiner @3 3 UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION L.S., Harris et al. I
Inventofls rs in the above-ideritified patent It. is certified that error appea by corrected as shown below:
and that: said Letters Patent are here Col. 1, lines*4354, the lower left portion of the structural formula should ,be 1 s I 3. 0 Col. 2, line "p.o." should be I.V.-.
-- S'igried and sealed this 9th day of July 197A.
(SEAL) Attest: v McCOY lyl. GIBSON, JR. c. MARSHALL DANN Attesting Officer Commissioner of Patents
US00283435A 1972-08-24 1972-08-24 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent Expired - Lifetime US3795736A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28343572A 1972-08-24 1972-08-24

Publications (1)

Publication Number Publication Date
US3795736A true US3795736A (en) 1974-03-05

Family

ID=23086056

Family Applications (1)

Application Number Title Priority Date Filing Date
US00283435A Expired - Lifetime US3795736A (en) 1972-08-24 1972-08-24 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent

Country Status (1)

Country Link
US (1) US3795736A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136183A (en) * 1976-08-04 1979-01-23 Abbott Laboratories Benzopyranopyridines as antiglaucoma agents
US4247557A (en) * 1976-08-04 1981-01-27 Abbott Laboratories Benzopyranopyridines as antiglaucoma agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136183A (en) * 1976-08-04 1979-01-23 Abbott Laboratories Benzopyranopyridines as antiglaucoma agents
US4247557A (en) * 1976-08-04 1981-01-27 Abbott Laboratories Benzopyranopyridines as antiglaucoma agents

Similar Documents

Publication Publication Date Title
US3773955A (en) Analgetic compositions
KR19990067527A (en) Use of efinastin for the treatment of pain
HU206042B (en) Process for producing pharmaceutical compositions comprising indole-3-carboxylic acid-endo-8-methyl-8-azabicyclo/3.2.1./oct-3-yl ester and/or 1,2,3-9-tetrahydro-9-methyl-3-(2-methyl-1h-imidazol-1-yl)-methyl-4h-carbazol-4-one, with an activity preventing or reducing opiate-, alcohol- and nicotine-dependence
CA2586254A1 (en) Therapeutic agent for neuropathic pain
Keats et al. Analgesic activity and toxic effects of acetylmethadol isomers in man
US3679798A (en) Composition comprising arylaminooxazoline and antichloligeneric agent
Carlson et al. A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain
US3439094A (en) Analgesic compositions containing namol xenyrate,caffeine and acetyl-rho-aminophenol
US3795736A (en) 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent
US4032637A (en) Method of promoting sleep
US2817623A (en) Tabernanthine, ibogaine containing analgesic compositions
US3852453A (en) Method of enhancing vincamine compositions
US3755586A (en) Anti tussive compositions containing piperidine derivatives
DE3525390C2 (en)
JPS6416721A (en) Antioxidant
KR100352898B1 (en) Pharmaceuticals containing novel 3-benzoyl-3,7-diazabicyclo [3,3,1] nonan-compounds
CA1139670A (en) Process and composition for reducing blood pressure in animals
US3733423A (en) Hydrogenated ergot alkaloid compositions and methods of using same
US3256149A (en) Compositions comprising an alkaloid of mitragyna speciosa and methods of using same
Oosterlinck et al. Preliminary clinical experience with meptazinol, a new analgesic
US3743732A (en) Process for suppressing the tremor of parkinson's syndrome
US3777028A (en) 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1)-benzopyrano(3,4-d)pyridine as an anti-diarrheal agent
US3244588A (en) Method of inhibiting cough with thiaxanthenol derivatives
EP0071563B1 (en) Trans-dihyldrolisuride antipsychotic
US3567828A (en) Organic compounds